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Background: Adelmidrol is a semisynthetic derivative of azelaic acid and analogue of the anti-inflammatory
compound palmitoylethanolamide (PEA). Based upon its physicochemical properties, adelmidrol is suitable for
topical application. The main objective of the present study was to evaluate the efficacy of a topical adelmidrol
emulsion on early and late inflammatory responses in hypersensitive dogs. Repeated intradermal injections of
Ascaris suum extract were performed in both lateral thoracic areas of six conscious hypersensitive Beagle dogs,
topically treated during 8 consecutive days. Adelmidrol (2%) was applied to one side and vehicle to the other.
24 hours after the last antigen challenge, two biopsies (adelmidrol- and vehicle-treated side) were obtained for
each dog at the antigen injection site.
Results: A significant reduction in the antigen-induced wheal areas was observed on the 4th and 7th day of
adelmidrol treatment. Moreover, cutaneous mast cell numbers were significantly decreased in biopsies obtained
after 8 consecutive days of topical adelmidrol treatment.
Conclusions: The results obtained in the present study show that topical treatment with adelmidrol might
represent a new therapeutic tool in controlling the early and late allergic inflammatory skin responses in
companion animals.
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Adelmidrol is the diethanolamide derivative of azelaic
acid, i.e., naturally occurring dicarboxylic acid that has
long proven to be an effective topical treatment for
human inflammatory skin disorders [1], and whose
mechanism of action has been extensively investigated
[2]. Similar to the anti-inflammatory and anti-
nociceptive compound palmitoylethanolamide (PEA)
[3-12], adelmidrol belongs to the aliamide family [13,14],
a group of fatty acid derivatives with cannabimimetic
properties, able to control mast cell (MC) hyper-
reactivity in several pathophysiological and pathological
conditions [5,8,15-17]. We have recently found that PEA
down-modulates the release of both preformed and
newly-synthesized mediators from canine skin MCs* Correspondence: anna.puigdemont@uab.es
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reproduction in any medium, provided the orchallenged with immunologic stimuli [18]. Moreover, the
PEA analogue adelmidrol has been shown to negatively
control the behavior of canine skin MCs during patho-
physiological conditions (i.e. healing of experimental
wounds) [19]. In particular, a statistically significant in-
crease of intracytoplasmic granular content of dermal
MCs was shown in adelmidrol (2%)-treated wounds
compared to control, thus suggesting the compound is
effectively able to down-modulate skin MC degranula-
tion in dogs [19]. Furthermore, the local application of
adelmidrol confirmed the reduction in MC responses
during chronic experimental inflammation, as shown by
the significant decrease of mediators such as chymase
which are selectively expressed by MCs and intimately
involved in skin inflammation [20].
Mast cell hyperactivity is involved in the pathobiology
of several canine disorders [21-23], including those of a
dermatological nature [24,25]. In a canine model of al-
lergic dermatitis, i.e., spontaneous hypersensitivity to theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Schematic representation of the study timeline.
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triggers the immediate degranulation of MCs, resulting
in an early phase reaction (EPR), clinically manifested as
skin wheals [24,26-30]. The combined actions of newly-
synthesized and preformed mediators released by MCs
results in the subsequent transcription of inflammatory
cytokines and chemokines that ultimately drive the re-
cruitment of inflammatory cells to the site of antigen in-
jection. This process is known as the late phase reaction
(LPR) and can become chronic [31,32]. We have recently
found that a single oral dose of PEA (10 mg/kg) reduced
significantly the antigen-induced skin wheal reaction in
hypersensitive Beagle dogs [33]. Moreover, the repeated
administration of PEA (5 and 10 mg/kg, intraperitoneal)
has been shown to play a protective role against inflam-
mation in experimental allergic dermatitis [34]. Unlike
PEA, which is a highly lipophilic compound, adelmidrol
is more suited to topical application, because exhibits
both hydrophilic and lipophilic features (i.e,. amphi-
pathic properties), which facilitates its absorbtion into
the skin, whose epidermis is composed of alternating
lipophilic and hydrophilic layers. A 4-week topical treat-
ment with adelmidrol 2% emulsion in children affected
by mild atopic dermatitis resulted in complete resolution
in 80% of cases, with no side effects and no relapses at
8-week follow up [35]. In the last decades, the use of
topical therapy in veterinary dermatology has increased
and is especially recommended for localized allergic skin
lesions, where it is currently regarded as a sole therapy
or an adjunctive therapy minimizing the need for sys-
temic treatments [36,37]. Based on the aforementioned
background, the aim of the present study was to investi-
gate whether, similar to PEA [33], adelmidrol was able
to limit the inflammatory allergic response upon topical
application.
Methods
Drugs, chemicals, and reagents
Adelmidrol (2%) and vehicle emulsions were purchased
by Innovet (Milano, Italy). A. suum extract was pur-
chased from Greer Laboratories (Lenoir, NC, United
States). Evans blue dye and histamine diphosphate salt
were obtained from Sigma-Aldrich (St. Louis, MD,
United States).
Animals
Six spontaneously hypersensitive Beagle dogs (four
females and two males) with mean body weights of 15.2
± 0.7 kg were used in this study. No drugs or additional
treatments were given during the study, except sedatives,
administered prior to obtaining the biopsies. All experi-
ments and procedures were performed in accordance
with European regulations governing the care and treat-
ment of laboratory animals and were approved by theAnimal Care and Use Committee of the Universitat
Autònoma de Barcelona.
Experimental protocol
The method used was based on measurement of the in-
hibition of the wheal area induced, in the right and left
shaved lateral thoracic areas (25 cm2 per area) of dogs,
by intradermal injections of an A. suum extract solution
(0.01% w/v), before and after treatments. Topical solu-
tions (4 ml) of adelmidrol 2% and vehicle were applied
three times a day for 8 consecutive days in the injected
areas. In order to better visualize wheal areas, a 2% w/v
Evans blue dye solution in saline was given intravenously
(0.4 mL/kg) 30 min before each antigen injection. Three
challenges were performed before (first challenge), on
the 4th day (second challenge) and the 7th day (third
challenge) of treatment, using a Hamilton syringe (type
701LT) (Reno, NV, United States). The results from the
first challenge (i.e., performed prior to treatment) were
taken as the baseline response. Each intradermal antigen
challenge was performed 10 minutes before the second
daily treatment application (Figure 1). Histamine
(0.001% w/v) and saline were also injected, as positive
and negative controls, respectively.
Planimetry
10 minutes after intradermal challenge with A. suum ex-
tract solution, wheal areas were traced on an acetate
sheet over the reaction site with indelible ink. Areas
were then analyzed with an image analyzer MIP 4
ADVANCED (Digital Image System, Barcelona, Spain).
Collection of skin biopsy specimens
24 hours after the third challenge, dogs received a local
anaesthesia consisting of a subcutaneous injection of
lidocaine (2%) without adrenaline, and two 6-mm punch
Cerrato et al. BMC Veterinary Research 2012, 8:230 Page 3 of 8
http://www.biomedcentral.com/1746-6148/8/230skin biopsies (i.e., adelmidrol- and vehicle-treated side)
were collected at injection sites.Histopathology
All biopsy specimens were fixed in neutral buffered for-
malin and embedded in paraffin for routine processing.
5 μm sections were stained with haematoxylin-eosin and
toluidine blue (to visualize MC metachromatic granules).
Dermis oedema and cell recruitment were graded semi-
quantitatively on an arbitrary scale [i.e., -/+ (0-1 cell); +
+(1-3 cells); +++ (3-6 cells); ++++ (>6 cells)], on a x400
total magnification microscope. In particular, MC counts
(per unit area) were determined on six randomly
selected sections for each of the three different dermal
layers, identified according to the known vascular plex-
uses subdivision in the skin, i.e., superficial (just beneath
the epidermis), middle (around middle portions of hair
follicles and sebaceous glands) and deep dermis (around
the inferior portion of hair follicles and dermis/subcutis
interface). Histological slides were read blindly with re-
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Figure 2 Mean inhibition percentage (± SEM) (n = 6) of wheal
areas induced in conscious hypersensitive Beagle dogs by A.
suum extract observed before, on the 4th and 7th day of
treatment with adelmidrol 2% or vehicle. **P < 0.01.Data analysis
To guarantee test reproducibility all experiments were
performed by the same investigator blinded to the ani-
mal’s treatment. Wheal areas were expressed in mm2 as
means ± standard error of the mean (mean ± SEM). Re-
sponse variability in wheal areas was analyzed using the
coefficient of variation (CV) before starting the treat-
ments. Results were expressed as the percentage of inhib-
ition observed for each challenge, comparing the antigen
wheal area obtained in the same dog in the adelmidrol-
treated side or vehicle-treated side versus the areas
obtained at baseline (t0). Wheal inhibition was calculated
with the following formula,
% inhibition ¼ tnarea mm
2ð Þ  t0 area mm2ð Þ
t0area mm2ð Þ  100
where t0 area corresponds to baseline value and tn area is
the area after adelmidrol or vehicle application, at a given
time.
Differences between means were analyzed using an
ANOVA test for paired measures and a Tukey’s multiple
comparison post-hoc test. Statistical significance was set
at P< 0.05 and P< 0.01.
Differences between MC numbers were compared
using the Student’s t-test for paired data with a level of
significance of P< 0.05 and P< 0.01.
Compliance with conditions for applying the afore-
mentioned tests was verified with the Kolmogorov-
Smirnov normality test.Results
Macroscopic findings
In order to assess the repeatability of wheal area meas-
ure over time, wheal areas induced by subsequent A.
suum extract injections in each dog were studied. Des-
pite the differences observed between dogs (CV > 10%),
no within-dog differences were observed (CV < 5%). For
this reason, the adelmidrol inhibitory effect in each dog
was calculated from its own basal value.
Figure 2 shows the mean inhibition percentage of
wheal areas induced in hypersensitive Beagle dogs by A.
suum extract before and after 3 and 6 consecutive days
of topical treatment with adelmidrol or vehicle, in com-
parison with baseline wheal areas. After 3 and 6 days of
topical adelmidrol treatment, a statistically significant re-
duction in wheal areas was observed (P = 0.001 and P =
0.003), reaching an inhibition of 19.9 ± 2.5 and 36.8 ±
3.5%, respectively. The difference between the adelmi-
drol inhibitory effect observed on day 4 and 7 was statis-
tically significant (P = 0.025). Conversely, the vehicle did
not exert any significant effect on the wheal formation at
any time (P = 0.054 and P = 0.3, at the two observation
times respectively) (Figure 2).
Microscopic findings
24 hours after the third intradermal allergen challenge
(i.e., 8 days after starting treatment) a skin biopsy from
each treatment side was obtained and the inflammatory
reaction was histologically evaluated. The analysis
revealed that oedema was evident within the vehicle-
treated area in all six cases, while only two out of six
dogs presented oedema in the adelmidrol-treated side.
Furthermore, in the adelmidrol-treated side a slight, al-
beit not statistically significant, reduction in the recruit-
ment of eosinophils, lymphocytes, monocytes and
Table 1 Quantification of mast cells (3 fields of 400X) in
biopsies collected after topical vehicle and 2%
adelmidrol treatment
MAST CELL NUMBER OBSERVED AFTER VEHICLE AND ADELMIDROL
TREATMENT
Investigated
dermal layer
ADELMIDROL VEHICLE P-VALUE
(MEAN ± SEM) (MEAN ± SEM)
Superficial 3.8 ± 0.6 6.6 ± 1.1 0.03
Middle 1.1 ± 0.3 2.9 ± 0.6 0.02
Deep 0.4 ± 0.2 1.3 ± 0.3 0.01
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treated side. Mast cell numbers decreased in almost all
biopsies after treatment and for this reason a more ac-
curate quantification was performed.
Using toluidine blue staining for dermal MC counts, a
highly significant reduction was observed in the
adelmidrol-treated side (P = 0.0003) (Figure 3). Quanti-
tative evaluation of MCs in the three different dermal
layers that were studied (i.e., superficial, middle and deep
dermis) revealed a significant decrease in MC numbers
in the adelmidrol-treated side compared to the vehicle-
treated side (Table 1).
Discussion
The present study shows, for the first time, that adelmi-
drol effects are evident in both the EPR and LPR in
spontaneous hypersensitive Beagle dogs after intrader-
mal antigen challenge. Topical treatment with adelmi-
drol (2%) for 3 and 6 consecutive days resulted in a
significantly reduced skin wheal response compared to
baseline values. Conversely, the vehicle-treated side did
not show any significant wheal reduction at any treat-
ment time, thus confirming, albeit indirectly, the lack of
systemic absorption of adelmidrol after topical
application.
Magnitude of the inhibitory effect on skin wheal
Adelmidrol topical application inhibited wheal formation
by about 20 and 37%, after 3 and 6 days of treatment, re-
spectively. Results were of about the same magnitude as
those observed in a previous study performed with a sin-
gle oral dose of the aliamide parent molecule PEA in
hypersensitive Beagle dogs [33]. The administration of
PEA before intradermal antigen challenge resulted in a
significant 29 and 32% reduction in wheal area, respect-
ively, with doses of 10 and 30 mg/Kg [33].
A number of studies on the inhibitory effects of differ-
ent drugs on skin wheal response in dogs have been
published. The key findings are summarized in Table 2.a
Figure 3 Mast cells obtained from Beagle skin biopsies after toluidine
treated side (a) and adelmidrol-treated side (b).The effect of corticosteroids (both oral or topical) on
intradermally-induced skin wheal ranges from lack of ef-
fect [38,39] up to 45% inhibition [40-43], with the only
exception of one single study (72% inhibition rate) [44].
Interestingly, similar results are observed in allergic
human patients (i.e., 30-40% inhibition) [45], and better
outcomes are known to occur with longer treatment
[46]. The inhibitory effect of oral antihistamines on
antigen-induced skin wheal in dogs is on average 50%
[27,43], with obviously better results with histamine
challenge [47,48] (Table 2). Interestingly, topically ap-
plied sodium cromoglycate (i.e., a MC stabilizer agent)
inhibits the skin wheal in atopic human patients by only
27% [49].
On the whole, one may consider wheal inhibition by
topically applied adelmidrol to be almost the same order
of magnitude as that of topical corticosteroids and lower
than the value achieved after oral administration of anti-
histamines, whose clinical validity and utility remain
doubtful [37]. Moreover, similarly to corticosteroids,
treatment time could be a crucial factor [46] and longer
treatment with topical adelmidrol (i.e., over 7 days)
could increase the effect size.
The purported mechanism involves mast cell control
Mast cells are considered to be major players of EPR
[50-52]. Within minutes of antigen exposure, theyb
blue staining (black arrows). Histological sections from the vehicle-
Table 2 Main studies on the inhibition of skin wheal response in dogs - key findings
Subjects Intradermal
challenge
Drug Administration
route
Treatment
time
Wheal inhibition vs
baseline
Ref
Healthy Beagle dogs Anti-canine IgE Corticosteroids (prednisolone) Oral Twice daily
for 3 days
No effect [38]
Dogs with pruritic
dermatitis
Histamine (5
different
dilutions)
Corticosteroids (hydrocortisone
1%)
Topical
(conditioner)
Twice weekly
for 6 weeks
No effect [39]
Healthy Beagle dogs Histamine Corticosteroids (betamethasone) Topical (otic
preparation)
Twice daily
for 2 weeks
5.9% [40]
Healthy Beagle dogs D. farinae Corticosteroids (betamethasone) Topical (otic
preparation)
Twice daily
for 2 weeks
9% [40]
Healthy Beagle dogs Cynodon
dactylon
Corticosteroids (betamethasone) Topical (otic
preparation)
Twice daily
for 2 weeks
9.8% [40]
Healthy Beagle dogs Anti-canine IgE Corticosteroids (hydrocortisone
1%)
Topical
(conditioner)
3 days 14% (*) [41]
Healthy dogs Anti-canine IgE
(different
dilutions)
Corticosteroids (triamcinolone) Topical
(solution)
7 days 24-45% (§) depending on
the stimulus concentration
[42]
Healthy mixed breed
dogs
D. farinae Corticosteroids (prednisone) Oral 7 days 41% [43]
Atopic Maltese-beagle
cross-breed dogs
Anti-canine IgE Corticosteroids (hydrocortisone
aceponate)
Topical (spray) 7 days 72% [44]
Healthy mixed breed
dogs
D. farinae Antihistamines (cetrizine) Oral 14 days 49% [43]
Spontaneously Ascaris
hypersensitive Beagle
dogs
A. suum Antihistamines (rupatadine) Oral Single pre-
treatment
dose
35, 67 and 84% (#) [27]
Spontaneously Ascaris
hypersensitive Beagle
dogs
A. suum Antihistamines (loratadine) Oral Single pre-
treatment
dose
34, 61 and 66% (#) [27]
Healthy Beagle dogs PAF Antihistamines (rupatadine) Oral Single pre-
treatment
dose
30% to 45% (¥) [47]
Healthy Beagle dogs Histamine Antihistamines (rupatadine) Oral Single pre-
treatment
dose
50% to 80% (¥) [47]
Healthy Beagle dogs Histamine Antihistamines (cetrizine,
loratadine, rupatadine,
levocabastine)
Oral Single pre-
treatment
dose
70% to 80% (**) [48]
Healthy Beagle dogs Histamine Antihistamines (cetrizine,
loratadine, rupatadine,
levocabastine)
Oral Single pre-
treatment
dose
70% to 80% (**) [48]
(*) versus placebo group;
(§) versus vehicle-treated side;
(#) peak activity at 0.1, 1 and 10 mg/Kg respectively, 2 to 4 hrs after administration;
(¥) peak activity, 4 h after administration, depending on the dose;
(**) peak activity, 4 h after administration, depending on the compound and the dose.
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tryptase, chymase) and membrane-derived eicosanoids
leading to the so-called ‘wheal and flare’ reaction of the
skin [53,54]. The ability of aliamides (to whose family
the tested compound belongs) to down-modulate the re-
lease of bioactive mediators from MCs [18-20] may thus
represent the mechanism of the inhibitory effect on
wheal areas, observed in the present study. Indeed, adel-
midrol can down-modulate skin MC degranulation both
during pathophysiological canine conditions [19] and in
experimental chronic inflammation [20]. Moreover, thesignificant increase in the percentage inhibition of wheal
area observed from the 4th to 7th day of treatment (from
about 20 to 37% inhibition) may depend on the
purported mechanism of action of the compound, i.e.
the down-modulation of hyperactive skin MCs [19,20],
which represents an endogenous tuning mechanism -
and thus a gradual, progressive phenomenon - rather
than an immediate ‘pharmacological’ switch-off
effect [55].
The present study also demonstrates the inhibitory ef-
fect of adelmidrol on the increased MC number observed
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end of the 8-day-treatment). Indeed, the adelmidrol-
treated side showed 42%, 62% and 69% less MCs in the
superficial, middle and deep dermis respectively, com-
pared to the vehicle-treated side. Although the baseline
data are missing (the study was not designed to have t0 bi-
opsies), this finding suggests that adelmidrol limited the
LPR by decreasing skin MC hyperplasia following antigen
challenge. Thus, both the functional and quantitative con-
trol of MCs might explain the observed anti-allergic effect
of the topical treatment with adelmidrol. Indeed, similar
findings emerged from a study on a model of chronic in-
flammation, where the local administration of adelmidrol
both down-modulated MC degranulation and prevented
numerical increase of MC numbers [20]. Interestingly,
topical corticosteroids decrease MC numbers in humans
[56], without any apparent effect on dogs [44].
Whether the effect on MC number observed in the
present study depends on the inhibition of MC prolifera-
tion or maturation from progenitors, both resident and
recruited from circulation, could not be tested by the
techniques used in here. Both hypotheses may be pos-
sible, since the adelmidrol analogue PEA has been
shown to (i) down-modulate keratinocyte production of
the inflammatory cytokines [34], responsible for the re-
cruitment of MCs [57]; and (ii) limit MC release of
nerve growth factor [16], a neurotrophin that promotes
chemotaxis of MCs as well as their maturation and de-
granulation [55,58,59]. Moreover, a recent study has
shown the existence of an inhibitory “endocannabinoid
tone” of skin MC biology, with skin MCs utilizing endo-
cannabinoid signaling to limit not only their own activa-
tion/degranulation but also their maturation from
resident progenitor cells [60]. This finding is particularly
interesting since aliamides share several aspects of their
biochemistry, metabolism and pharmacology with endo-
cannabinoids and have been referred to as endocannabi-
noid-like, cannabimimetic compounds, or even indirect
endocannabinoids [61,62]. Moreover, endocannabinoid
receptors (i.e., CB1 and CB2) have been discovered in
the canine skin and found to increase in diseased condi-
tions, such as atopic dermatitis [63]. Finally, one should
also consider that adelmidrol is a lipid amide and epider-
mal cells express the respective degrading enzymes (e.g.,
fatty acid amide hydrolase) [64]. Thus topically applied
adelmidrol can be partially cleaved to release azelaic
acid, which in turn might contribute to the observed ef-
fect, lessening the inflammatory phenotype of keratino-
cytes [2]. Importantly, no sign of irritation or any
adverse effect was noticed during the present study.
Practical considerations
From a practical point of view, the present findings sug-
gest that adelmidrol could find a place in the managementof hypersensitive skin disorders in the dog, where topical
treatments are currently preferred to systemic ones for
localized lesions characterizing the less severe stages of the
disease. Alternatively, adelmidrol could be applied as an
adjunct to systemic treatments for a “dual-site action” in
selected cases, as suggested for more classical topical tools
[37]. The most frequently used topical treatments for ca-
nine allergic skin diseases are glucocorticoid formulations
and tacrolimus oinment. Both approaches are effective,
even though tacrolimus has a slow onset of action, and
both exert adverse effects (i.e., mild irritation, cutaneous
atrophy, superficial follicular cysts, and increased suscepti-
bility to skin infection) that, although mild, can prejudice
owner compliance and lengthen recovery [37].
Conclusions
Intradermal injection of allergic-inflammatory stimuli,
with measurement of immediate wheal reaction and
later dermal cellular infiltrates has been considered a
useful technique for objectively documenting the anti-
inflammatory effect of topical preparations in dogs [42].
The present study evaluated the effect of the topical
daily application of the aliamide adelmidrol on the ca-
nine skin response to intradermal allergen challenge and
confirmed its anti-inflammatory effect. In particular, the
tested aliamide significantly reduced both EPR and LPR
in hypersensitive dogs. A significant decrease in acute
inflammation response and MC numbers was observed,
without any sign of irritation or adverse effect. Even
though further and more detailed molecular studies are
needed to confirm the results and broaden knowledge
on the mechanisms involved, the present findings sug-
gest that adelmidrol emulsion could represent a valuable
and safe tool in the armamentarium for canine inflam-
matory allergic skin disorders. The effects on wheal and
MC numbers provide a sound basis for an anti-
inflammatory drug sparing effect, and predict adelmidrol
to be profitably combined with oral treatments for an
optimal dual site therapy, i.e. outside-inside approach,
currently the most preferred route for managing canine
hypersensitive skin disorders [37].
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